Public Groupactive 1 week, 3 days ago
Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered serious bleeding events. Pharmaceutical firms, which includes the makers of Xarelto, possess a duty to ensure that their drugs are reasonably safe for use – and failure to perform so may be grounds for compensation. Our lawyers are functioning hard to have those hurt by the drug the compensation they may be entitled to.
While bleeding can be a frequent complication associated with anticoagulants, it has been alleged that Xarelto is a lot more dangerous than conventional blood thinners simply because no antidote exists to reverse its blood-thinning effects. This implies that, in the occasion of an emergency, individuals may possibly be at risk for irreversible bleeding troubles, like life-threatening internal and gastrointestinal hemorrhaging.
In the event you or a loved one suffered a severe bleeding event after taking Xarelto, you might have legal recourse. For more details, contact us right now to have your case reviewed, free of charge of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are seeking compensation from Bayer and Janssen for past and future medical bills, lost wages, pain and suffering and, in circumstances of death, funeral costs. Moreover, they may be in search of punitive damages, that are generally awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding in the occasion of an emergency. Plaintiffs inside the lawsuits allege severe and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user within the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
when was xarelto approved in europe is linked to significant bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing harmful clotting.
Visit this page for much more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys inside the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.
Sorry, there was no activity found. Please try a different filter.